AI Drug Discovery Startups Secure Funding
Two startups using AI for drug discovery have announced new funding rounds. Pharmacelera, which applies quantum mechanics and AI, raised €6 million to expand its platform in the U.S. market. Separately, Peptris secured ₹70 crore in a Series A round to advance its AI engine for drug repurposing and new chemical entity initiatives.
- The global market for AI in drug discovery was valued at approximately $2.58 billion in 2025 and is projected to reach over $10.29 billion by 2031, driven by the need to reduce the average $2.6 billion cost of bringing a single new drug to market. - Pharmacelera's platform, which they call QaiM, combines quantum mechanics with AI to search a massive theoretical "exaSpace" of trillions of molecules, a process they claim is up to 75,000 times faster than other AI-led approaches. - Peptris employs a "drug rescue" strategy, using its AI to find new applications for drugs that have been proven safe in human trials but were shelved after failing to be effective for their original intended disease. - One of Peptris's repurposed drug candidates, identified by its AI platform, is for Duchenne muscular dystrophy (DMD), a rare genetic disorder that causes progressive muscle degeneration. - The work at these startups is done by professionals in roles like Computational Biologist, who uses computer models to simulate biological systems, and Bioinformatics Scientist, who develops algorithms to analyze large biological datasets like genomic sequences. - A key technology in this field is the use of generative AI models, similar to those that create art or text, to design entirely new molecules from scratch (*de novo* drug design) with specific properties needed to fight a disease. - The founders of these startups often have deep technical backgrounds; for example, Pharmacelera co-founders Enric Gibert (CEO) and Enric Herrero (CTO) both hold PhDs in Computer Engineering and previously worked at Intel. - These companies operate on a business-to-business model, partnering with large pharmaceutical firms to co-develop or license the assets they discover, rather than taking the drugs all the way to market themselves.
